Toujeo

Sanofi shows off positive PhIII trial results for Toujeo, opening the door to a new group of diabetes patients
Sanofi shows off positive PhIII trial results for Toujeo, opening the door to a new group of diabetes patients
Endpoints
Sanofi
clinical trials
type 1 diabetes
insulin
Toujeo
Flag link:
Sanofi’s high-capacity insulin pen wins FDA nod
Sanofi’s high-capacity insulin pen wins FDA nod
Drug Delivery Business News
Sanofi
insulin
insulin pen
FDA
devices
Toujeo
diabetes
Flag link:
Sanofi touts head-to-head comparison of long-acting insulin products
Sanofi touts head-to-head comparison of long-acting insulin products
Drug Delivery Business News
Sanofi
insulin
diabetes
Toujeo
long-acting insulin
Novo Nordisk
Tresiba
Flag link:
EASD: Sanofi's Toujeo bests Lantus at holding off hypoglycemia, studies show
EASD: Sanofi's Toujeo bests Lantus at holding off hypoglycemia, studies show
Fierce Pharma
Sanofi
EASD
Toujeo
Lantus
hypoglycemia
diabetes
Flag link:
Sanofi boasts observational hypoglycemia rates for Toujeo insulin injection
Sanofi boasts observational hypoglycemia rates for Toujeo insulin injection
Mass Device
Sanofi
Toujeo
diabetes
insulin
Flag link:
The FDA issues untitled letters to Sanofi and Celgene over distracting ads
The FDA issues untitled letters to Sanofi and Celgene over distracting ads
Medical Marketing and Media
FDA
drug ads
Sanofi
Celgene
Toujeo
Otezla
Flag link:
Novo combats talk of insulin price war with 'moderate premium' on brand-new Tresiba
Novo combats talk of insulin price war with 'moderate premium' on brand-new Tresiba
Fierce Pharma
Novo Nordisk
insulin
Toujeo
Tresiba
diabetes
Sanofi
Flag link:
Novo Nordisk says any tussle with Sanofi's Toujeo will come down to formulary access
Novo Nordisk says any tussle with Sanofi's Toujeo will come down to formulary access
Medical Marketing and Media
Sanofi
Novo Nordisk
Toujeo
formulary
Tresiba
insulin
diabetes
Flag link:
Sanofi digs in heels, won't discount Lantus insulin successor Toujeo
Sanofi digs in heels, won't discount Lantus insulin successor Toujeo
BioPharma Dive
Sanofi
insulin
diabetes
Toujeo
Lantus
Flag link:
Confirmed: Sanofi's Toujeo launches in US Monday, setting up diabetes race
Confirmed: Sanofi's Toujeo launches in US Monday, setting up diabetes race
BioPharma Dive
Sanofi
Toujeo
diabetes
drug launches
Flag link:
11 promising drugs poised to be the next billion-dollar blockbusters
11 promising drugs poised to be the next billion-dollar blockbusters
Yahoo/Business Insider
Opdivo
Praluent
LCZ696
lumacaftor
Viekira Pak
evolocumab
Gardasil 9
brexpiprazole
Toujeo
Cosentyx
Bristol-Myers Squibb
Regeneron
Sanofi
Novartis
Pfizer
AbbVie
Amge
Astellas
Merck
Otsuka
Lundbeck
Vertex Pharmaceuticals
Flag link:
Sanofi to launch Toujeo diabetes drug in U.S. on Monday -source
Sanofi to launch Toujeo diabetes drug in U.S. on Monday -source
Yahoo/Reuters
Sanofi
Toujeo
diabetes
drug launches
Flag link:
Sanofi diabetes drug Toujeo wins European green light
Sanofi diabetes drug Toujeo wins European green light
Yahoo/Reuters
Sanofi
Toujeo
Europe
diabetes
Flag link:
Sanofi's new Lantus may not be the new Lantus
Sanofi's new Lantus may not be the new Lantus
Medical Marketing and Media
Sanofi
diabetes
Toujeo
Lantus
Flag link:
FDA OKs Sanofi's Toujeo. Will a diabetes drug price war follow?
FDA OKs Sanofi's Toujeo. Will a diabetes drug price war follow?
Fierce Biotech
Sanofi
diabetes
Toujeo
drug pricing
Lantus
Tresiba
Novo Nordisk
Flag link:
Sanofi's diabetes drug Toujeo gets U.S. approval, label disappoints
Sanofi's diabetes drug Toujeo gets U.S. approval, label disappoints
Yahoo/Reuters
Sanofi
Toujeo
FDA. diabetes
Flag link:
FirstWord Lists – The drugs that will shape 2015
FirstWord Lists – The drugs that will shape 2015
First Word Pharma
Harvoni
Viekira Pak
Gilead Sciences
AbbVie
alirocumab
evolocumab
Amgen
Regeneron
Sanofi
Opdivo
Keytruda
Merck
Bristol-Myers Squibb
Novartis
CTL019
Zarxio
Pfizer
palbociclib
Saxenda
Trulicity
Afrezza
MannKind
Eli Lilly
Novo Nordisk
LCZ696
Toujeo
Breo Ellipta
GED-0301
Celgene
BiogenIdec
Flag link:
Sanofi Still Ahead Of Novo Nordisk In Insulin Drug Race
Sanofi Still Ahead Of Novo Nordisk In Insulin Drug Race
Bidness Etc.
Sanofi
Novo Nordisk
diabetes
insulin
Lantus
Tresiba
Toujeo
Flag link:
Sanofi says FDA accepts filing for new diabetes drug Toujeo
Sanofi says FDA accepts filing for new diabetes drug Toujeo
Yahoo/Reuters
FDA
diabetes
Toujeo
Sanofi
Flag link:
New rivals to top diabetes drug Lantus show promise in studies
New rivals to top diabetes drug Lantus show promise in studies
Yahoo/Reuters
diabetes
Lantus
insulin
Sanofi
Toujeo
Eli Lilly
Flag link: